Mindfulness: a Novel Approach for the Management of Diabetes-related Distress

The purpose of this study is to evaluate the impact of stress reduction on physiological and psychological variables in adults with Type 2 diabetes (T2DM) who have moderate to severe levels of diabetes-related emotional distress. Subjects will be randomized to one of two interventions. We will evaluate the impact of the interventions on glucose metabolism, blood pressure, diabetes-related distress and quality of life. Additionally, we will investigate the role of neuroendocrine dysfunction, systemic inflammation and diabetes self-care practices as mediators in the relationship between increased stress, adverse glucose metabolism and elevated blood pressure in those subjects with T2DM.

Study Overview

Study Type

Interventional

Enrollment (Actual)

78

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • University of North Carolina

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age > 30 years
  2. Male or female
  3. Duration of diabetes 1-15 years from time of initial diagnosis
  4. Diagnosis of T2DM made/confirmed by physician
  5. Completed diabetes education in the past
  6. Most recent HgA1c >7%; measurement must be within the past 6 months either in physicians office or at the Thriving with Diabetes Boot Camp Class
  7. Treatment for diabetes must include any or all of the following modalities:

    diet, exercise, oral medications, insulin or other injectable diabetic medication

  8. Score > 30 on the Problem Area in Diabetes (PAID) Questionnaire
  9. Able to use a glucometer for self-monitoring of blood glucose values
  10. Most recent clinic blood pressure less than 180/95

Exclusion Criteria:

  1. History of ketoacidosis
  2. Age at diagnosis of T2DM < 30 years
  3. Score >15 on the PHQ-9
  4. Previous training in relaxation or meditation techniques
  5. Current practice of yoga, tai chi or any other mind-body movement for > 60 minutes per week
  6. Current use of a psychoactive drug for less than 3 months or not yet on a stable dose
  7. Inability to participate fully or behave appropriately in the group treatment setting, as observed by baseline acknowledgement of substance abuse, psychotic episode(s), psychiatric hospitalization or history of self- harm within the past 2 years, or current suicidal or homicidal ideation
  8. Inability to complete standardized instruments because of a cognitive deficit or language barrier
  9. Current use or use within the past 3 months of oral glucocorticoids, excluding intraocular, topical or inhaled preparations
  10. History of inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease
  11. Use of immune modulating agents
  12. Night shift work or other type of schedule in which sleep wake cycle is disrupted
  13. Women who consume > 7 alcoholic drinks per week and men who consume > 14 drinks per week
  14. Current use or history of daily tobacco use within the past 1 year
  15. End stage renal failure on dialysis
  16. Pregnancy or post partum <3 months
  17. Subjects with known secondary causes of hypertension including renal artery stenosis, pheochromocytoma, coarctation of aorta, hyperaldosteronemia
  18. Non-dominant arm circumference > 46cm
  19. Unwilling to accept randomization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mindfulness Based Stress Reduction
Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
Active Comparator: Health Education Control
Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HgA1c
Time Frame: 0,8,24 weeks
We will assess change in glycemic control using the A1c. It will be measured at baseline, immediately following the 8 week intervention and at 24 weeks from baseline.
0,8,24 weeks
Diabetes Distress
Time Frame: 0,8,24 weeks
The Problem Areas in Diabetes will be used to assess the change in diabetes emotional distress at baseline, immediately following the 8 week intervention and at 24 weeks from baseline
0,8,24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SF36 Physical Health Score
Time Frame: 0, 8,24 weeks
This measure is a patient reported outcome assessing general quality of life and will be assessed using the standardized SF36 tool.
0, 8,24 weeks
SF36 Mental Health Score
Time Frame: 0,8,24 weeks
This measure is a patient reported outcome assessing general quality of life and will be assessed using the standardized SF36 tool.
0,8,24 weeks
Mean 24 hour ambulatory systolic blood pressure
Time Frame: 0,8,24 weeks
Mean systolic blood pressure over 24 hours.
0,8,24 weeks
Mean 24 hour diastolic ambulatory blood pressure
Time Frame: 0,8,24 weeks
Mean diastolic blood pressure over 24 hours
0,8,24 weeks
HOMA-IR
Time Frame: 0,8,24 weeks
For those participants that are not using insulin, we will assess the degree of insulin resistance using the HOMA-IR, which is derived from the fasting insulin and fasting glucose.
0,8,24 weeks
Depression
Time Frame: 0,8,24 weeks
Using the Beck Depression Inventory we will assess symptoms of depression using this standardized patient reported outcome.
0,8,24 weeks
State Anxiety
Time Frame: 0,8,24 weeks
Using the State and Trait Anxiety Assessment we will measure "state" anxiety.
0,8,24 weeks
Trait Anxiety
Time Frame: 0,8,24 weeks
Using the State and Trait Anxiety Survey we will assess "trait" anxiety.
0,8,24 weeks
Social Support
Time Frame: 0,8,24 weeks
Using the Duke Social Support and Stress Scale we will assess the degree of social support participants report in their lives.
0,8,24 weeks
Coping Style
Time Frame: 0,8,24 weeks
Using the Coping Orientation to Problems Experienced Scale, we will evaluate the various coping styles and how they may change over time.
0,8,24 weeks
General Stress
Time Frame: 0,8,24 weeks
Using the Perceived Stress Scale we will assess general life stressors.
0,8,24 weeks
Cortisol 24 hour area under the curve
Time Frame: 0,8,24 weeks
Calculating the area under the curve for 24 hours we will assess cortisol secretion as a physiological assessment of stress
0,8,24 weeks
Cortisol Awakening Response
Time Frame: 0,8,24 weeks
We will measure the cortisol awakening response using measures of cortisol prior to arising and 30 minutes after waking up.
0,8,24 weeks
IL-6
Time Frame: 0,8, 24 weeks
IL-6 is an assessment of systemic inflammation and will be measured in serum.
0,8, 24 weeks
Summary of Diabetes Self-Care Activities
Time Frame: 0,8,24 weeks
This patient reported measure assesses the frequency which participants engage in self-care activities that are critical for DM self-management.
0,8,24 weeks
Average 24 hour glucose by continuous glucose monitor (cgm)
Time Frame: 0,8,24 weeks
Average cgm glucose over 24 hours
0,8,24 weeks
Average night time glucose
Time Frame: 0,8,24 weeks
Average night time glucose from 10pm-6am using continuous glucose monitoring values
0,8,24 weeks
Average day time glucose
Time Frame: 0,8,24 weeks
Average day time glucose from 6am-10pm using continuous glucose monitoring values
0,8,24 weeks
Block Food Frequency Questionnaire
Time Frame: Week 0
Standardized assessment of dietary patterns
Week 0
Mean Day Systolic Ambulatory Blood Pressure
Time Frame: 0,8,24 weeks
The average systolic blood pressure measured by ambulatory blood pressure monitoring between 6 am and 10 pm
0,8,24 weeks
Mean Day Diastolic Ambulatory Blood Pressure
Time Frame: 0,8,24 weeks
The average systolic blood pressure measured by ambulatory blood pressure monitoring between 6 am and 10 pm
0,8,24 weeks
Mean Night Systolic Ambulatory Blood Pressure
Time Frame: 0,8,24 weeks
The average systolic blood pressure measured by ambulatory blood pressure monitoring between 10 pm and 6 am.
0,8,24 weeks
Mean Night Diastolic Ambulatory Blood Pressure
Time Frame: 0,8,24 weeks
The average diastolic blood pressure measured by ambulatory blood pressure monitoring between 10 pm and 6 am.
0,8,24 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mindfulness
Time Frame: 0,8,24 weeks
To assess mindfulness we will utilize the Five Facet Mindfulness Questionnaire.
0,8,24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Laura A Young, MD, PhD, University of North Carolina

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2012

Primary Completion (Actual)

November 1, 2014

Study Completion (Actual)

December 1, 2015

Study Registration Dates

First Submitted

June 15, 2012

First Submitted That Met QC Criteria

March 4, 2013

First Posted (Estimate)

March 6, 2013

Study Record Updates

Last Update Posted (Actual)

April 19, 2017

Last Update Submitted That Met QC Criteria

April 17, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 11-0333

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress

Clinical Trials on Mindfulness Based Stress Reduction

3
Subscribe